Adjuvant treatment with osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, was recently incorporated into the standard treatment of EGFR-mutated early-stage non-small-cell lung cancer (NSCLC)4. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.